Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Equity Average (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Equity Average data on record, last reported at $263.7 million in Q3 2025.

  • For Q3 2025, Equity Average fell 28.44% year-over-year to $263.7 million; the TTM value through Sep 2025 reached $263.7 million, down 28.44%, while the annual FY2024 figure was $387.3 million, 11.11% down from the prior year.
  • Equity Average reached $263.7 million in Q3 2025 per ZNTL's latest filing, down from $284.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $502.6 million in Q3 2023 and bottomed at $263.7 million in Q3 2025.
  • Average Equity Average over 4 years is $396.5 million, with a median of $415.3 million recorded in 2023.
  • Peak YoY movement for Equity Average: rose 15.28% in 2023, then plummeted 32.27% in 2025.
  • A 4-year view of Equity Average shows it stood at $431.4 million in 2022, then grew by 6.55% to $459.6 million in 2023, then fell by 24.78% to $345.8 million in 2024, then dropped by 23.74% to $263.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $263.7 million in Q3 2025, $284.9 million in Q2 2025, and $316.3 million in Q1 2025.